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Abstract
Background: Multiple sclerosis (MS) varies considerably in its incidence and progression in females and males. In
spite of clinical evidence, relatively few studies have explored molecular mechanisms possibly involved in gender-
related differences. The present study describes possible cellular- and molecular-involved markers which are
differentially regulated in male and female rats and result in gender-dependent EAE evolution and progression.
Attention was focused on markers of myelination (MBP and PDGFaR) and neuronal distress and/or damage (GABA
synthesis enzymes, GAD65 and GAD67, NGF, BDNF and related receptors), in two CNS areas, i.e. spinal cord and
cerebellum, which are respectively severely and mildly affected by inflammation and demyelination. Tissues were
sampled during acute, relapse/remission and chronic phases and results were analysed by two-way ANOVA.
Results: 1. A strong gender-dependent difference in myelin (MBP) and myelin precursor (PDGFaR) marker mRNA
expression levels is observed in control animals in the spinal cord, but not in the cerebellum. This is the only
gender-dependent difference in the expression level of the indicated markers in healthy animals; 2. both PDGFaR
and MBP mRNAs in the spinal cord and MBP in the cerebellum are down-regulated during EAE in gender-
dependent manner; 3. in the cerebellum, the expression profile of neuron-associated markers (GAD65, GAD67) is
characterized by a substantial down-regulation during the inflammatory phase of the disease, which does not
differ between male and female rats (two-way ANOVA); 4. there is an up-regulation of NGF, trkA and p75 mRNA
expression in the early phases of the disease (14 and 21 days post-immunization), which is not different between
male and female.
Conclusions: It is reported herein that the regulation of markers involved in demyelination and neuroprotection
processes occurring during EAE, a well-established MS animal model, is gender- and time-dependent. These
findings might contribute to gender- and phase disease-based therapy strategies.
Keywords: experimental allergic encephalomyelitis, gender-related, rat, spinal cord, cerebellum, neurotrophins and
related receptors
Background
Multiple sclerosis (MS) is an inflammatory demyelinating
disease of the central nervous system (CNS), which can
progress over decades. The progressive failure of remyeli-
nation leads to the cumulative loss of axons, grey matter
atrophy and prevalent neurodegeneration responsible for
chronic disability and cognitive decline [1]. There is a
considerable difference in the way MS affects females
and males, as has been highlighted by epidemiology stu-
dies and MRI analyses [2-4]. The way of gender-influence
in MS is complex and still obscure. From a pathogenic
point of view, females tend to have stronger Th1-
mediated immune responses and are more prone to
develop autoimmune diseases, including MS [5]. How-
ever, gender might influence white matter establishment
and maintenance of the mature structure of white tracts,
thus affecting their repair capability. A review of in vivo
imaging studies suggests that gender-related differences
in white matter in the human brain exist in healthy sub-
jects [6] and affect in particular age-related changes in
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precentral, cingulate, and anterior temporal white matter
areas [7]. As well as in the normal brain, white matter
pathology seems also to differ in males and females in
several neurological and psychiatric conditions. For
example, in schizophrenia there is a subtle and gender-
dependent alteration in the forebrain commissures, and
the neurotoxic effect of metamphetamine on frontal
white matter seems to be less prominent in women than
in men [8]. Sex differences in lesion size, neuronal cell
loss, and mortality rates have been observed after ische-
mia and trauma [9]. Moreover, a gender effect in the pro-
gression of several neurodegenerative diseases has been
noted. Epidemiological data point to women’s proneness
to Alzheimer’s disease [10], and indicate that after trau-
matic brain injury (TBI) women show better recovery
than men [9].
Apart from this clinical evidence, on which several
gonadal steroids-oriented clinical trials have been based
[11], relatively few studies have explored possible mole-
cular mechanisms involved in gender-related differences.
In this context, there has been much speculation con-
cerning the gonadal hormone role in immune function
and cytokines production during inflammation, myelina-
tion, and neurodegeneration/neuroprotection [4,5,12],
but direct evidence regarding gender-related differences
in these and other critical molecular and cellular hall-
marks of the diseases is still very scanty.
We are exploring possible molecular determinants for
gender-dependent differences in inflammatory demyelinat-
ing diseases using experimental allergic encephalomyelitis
(EAE) in rats as a disease model for MS. EAE induced in
Dark Agouti rats is Th1 mediated, having a relapsing-
remitting course, and comprises also persistent demyelina-
tion, remyelination, neuronal distress and cognitive defects
[13-18]. In this model, we have demonstrated by liquid
chromatography-tandem mass spectrometry that the levels
of neuroactive steroids display sex, regional and temporal
differences in both control and EAE, and these changes
did not correlate to the plasma levels of gonadal hormones
[19,20].
In this paper data are presented regarding molecular
markers for oligodendrocyte precursor cells, myelin pro-
teins, neurotransmitters and neurotrophins in the course
of EAE. Attention was focused on the spinal cord as a
white matter-rich area in which most of the tissue is occu-
pied by heavily myelinated tracts that is severely affected
by inflammation and demyelination, and on the cerebel-
lum as a grey matter-rich area since ataxia is a common
symptom in EAE rats, and a cerebellar cortical atrophy
has been described late in the disease in spite of poor
inflammation and demyelination [21].
Results
Animals and disease progression
The clinical profile of EAE is reported in Figure 1, where
neurological disability score (A) and body weight graphs
(B) are shown. Animals develop clinical signs for EAE
starting from 7-8 days post-immunization (DPI), after
which disease progressed rapidly until 14 DPI (acute
phase). The first regression is not complete and at 21 DPI
there is a relapse, which is not so severe as the acute
phase. The recovery phase is followed until 40 DPI, when
a very slight disability still persists. The statistical analysis
by two-way ANOVA indicates that the course of the dis-
ease is different between male and female rats (p =
0.0028). The body weight curves show the physiological
profile in male and female control rats, and the expected
gain arrest in the acute phase, which is followed by a par-
tial recovery (B).
Histopathology was analysed at 14 DPI. At this stage,
a severe and diffuse inflammatory cellular infiltrate was
observed in the spinal cord (Figure 2A: control; Figure
2B-D: EAE) in perivascular and intraparenchymal
areas. The astroglial reaction was also analysed by
Figure 1 Clinical score evolution (A) and body weight variations (B) in experimental animals (control female: white triangle, control
male: white circle, EAE female: black triangle, EAE male: black circle). Significant differences were observed in the clinical disability score
between male and female animals (two-way ANOVA, gender effect, **p = 0.0028, F(1,649) = 9.027; days post-immunization (DPI) effect, *** p <
0.0001, F(27,649) = 54.32.
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Figure 2 Histopathology of the spinal cord in control and EAE animals was performed by E&E (A-D), GFAP-immunostaining for
astroglial reaction (E-H) and FluoroMyelin staining for white tractd and myelin sheaths (K-M and related inserts). Micrograph in A
illustrates a spinal cord hemi-sections in control, male rat; micrograph in B a spinal cord hemi-sections showing the extensive inflammatory
infiltrates in EAE, as detailed in high power micrographs in C and D. Arrows indicate the intraparenchimal infiltrates asterisk in C a perivascular
infiltrate. Image analysis indicates that there is a difference in the extension of inflammation infiltrate in female vs male EAE animals (N, Student’s
t test, p = 0.00249). Micrographs from E to H illustrate the astroglial reaction in EAE animals (F: female; H: male) with control animals (E: female;
G: male). Image analysis indicates that astroglial reaction is stronger in female than in male EAE animals (O, one way ANOVA and Tukey multiple
comparison test, **p < 0.01; ***p < 0.001). Micrographs from K to M illustrate white matter in EAE (I: female; M: male) compared with control
animals (K: female; L: male). The color inserts refer to high power magnification, to shown the myelin sheath morphology. The original image
has been processed using a deconvolution procedure. Image analysis indicates that demyelination is not different in female and male EAE
animals (one way ANOVA and Tukey multiple comparison test, **p < 0.01; ***p < 0.001). Graph bars: M, 100 μm; color insert 10 μm.
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GFAP-immunostaining (Figure 2E-H) and demyelina-
tion by FluoroMyelin histochemistry (Figure 2K-M).
Morphometric analysis of the investigated markers is
reported in Figure 2N-P. The semiquantitative evalua-
tion of the inflammation score reveals a slight but sig-
nificant difference between male and female rats,
having the female animals a lower score (Figure 2N).
The astroglial reaction observed in male and female
rats during EAE was stronger in female than in male
rats (Figure 2O). Demyelination, as analysed in the gra-
cile fasciculus of the lumbar spinal cord, was no differ-
ent in male and female rats.
At this stage, and as already reported in previously
published paper [13] very few cellular infiltrates were
found in cerebellum and cerebral cortex (not shown).
Myelin markers
In order to investigate possible gender effects on demyeli-
nation/remyelination during EAE in Dark-Agouti rats, the
expression level of myelin markers was analyzed in both
male and female rats at the different phases of the EAE, in
spinal cord and cerebellum. In particular, mRNA expres-
sion level was analyzed for PDGFaR, which is a marker
for the oligodendrocyte precursor cells (OPCs) responsible
for myelin repair in the mature CNS [22] and MBP, which
is one of the most abundant among the myelin proteins
[23]. In the spinal cord, PDGFaR mRNA expression in
healthy males is around 2.5 times higher than in healthy
females (p = 0.0175), whereas the MBP mRNA level is 5
times higher in males than in females (p = 0.0004) (Figure
3A, B). In both sexes, the expression of both genes was
down-regulated in all phases of the disease (Figure 3C, D)
and a significant difference was observed between females
and males (two-way ANOVA and Bonferroni post-test).
PDGFaR mRNA down-regulation is stronger in male than
in female at 14 and 21 DPI. MBP mRNA expression level
differs between male and female at 21 and 40 DPI. The
histochemical analysis of myelin during the acute phase of
EAE indicated that the decrease in myelin staining in the
gracile fasciculus was comparable in both male and female
rats (Figure 2C).
To determine whether the sex-dependent difference in
MBP mRNA expression also had an impact on protein
content, MBP protein levels were measured in the spinal
cord of control healthy rats using Western blot. The 17.5,
18.5 and 21.5 isoforms were studied, and a representative
Western-blot experiment has been included in Figure 4
(D). No differences between female and male rats were
observed in any of the investigated isoforms (Figure 4A, B,
C). A morphometric analysis of the myelin sheath in male
and female rats was also performed by measuring the G-
ratio of the lateral, dorsal and ventral funiculus of the
lumbar spinal cord in confocal images of FluoroMyelin
staining. No differences between male and female rats
were observed (data not shown).
In the cerebellum, no significant changes were observed
in the expression of PDGFaR mRNA between healthy
male and female rats and during the course of EAE (Figure
5A, C). On the contrary, MBP mRNA expression level was
down-regulated during EAE in both females and males.
Significant differences were observed in the expression of
the MBP gene in EAE animals (Figure 5B, D) at 40 DPI
between females and males, being lower in female than
male rats (Bonferroni test, ** p < 0.01).
GAD, neurotrophins and related receptors
In order to investigate markers for neuronal distress/
lesion, the expression level for mRNAs encoding for
GABA synthesis enzyme and neurotransmitter and neuro-
trophins was analyzed. No gender effect was observed in
the expression of mRNA encoding for the enzymes
GAD65 and GAD67 either in healthy or EAE animals (Fig-
ure 6A, B). However, the expression of GAD65 and
GAD67 mRNA during EAE was down-regulated in both
male and female rats. Significant differences were observed
at different phases of EAE. GAD65 and GAD 67 mRNA
levels displayed a recovery at 40 DPI.
The expression of BDNF, NGF neurotrophin receptors
trkA (high-affinity NGF receptor) and p75 (low affinity
NGF and BDNF receptor) was also studied during EAE in
both sexes in the cerebellum. No gender effect for any of
the investigated mRNAs was found in healthy animals
(Figure 7A, B, C, D). BDNF mRNA expression was not sig-
nificantly changed during the course of EAE (Figure 7E) in
both male and female rats. On the contrary, there was a
significant up-regulation of NGF mRNA expression level
in the acute, inflammatory phase of the disease in both
male and female rats (Figure 7F, 14 DPI), which was partly
attenuated, but not resolved, in the course of the disease
in female rats and resolved already at 21 days in male rats.
A slight, but significant and stable up-regulation of the
NGF low-affinity receptor p75 mRNA expression was
observed in both female and male rats (Figure 7G). An
up-regulation of the NGF high-affinity receptor trkA
mRNA expression level was also found in female and male
(Figure 7H).
Discussion
Gender bias in autoimmune diseases is a well-known and
hitherto unexplained fact. In particular, MS is more preva-
lent in females than in males, and this female predomi-
nance increases as time goes by. Gender appears to play a
critical role also in the progression of MS, suggesting that
not only immune reaction, but also remyelination, axonal
pathology and neural damage might be gender-dependent
[24]. In all cases, the histopathological and molecular
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mechanisms underlying the inherent differences in male
and female MS are still obscure [25].
In the present study molecular markers for myelin and
grey matter that are differentially regulated in male and
female rats in the experimental model of the disease
have been described. Two areas were investigated: the
spinal cord, which is the area with extensive inflamma-
tion and demyelination, and the cerebellum, in view of
Figure 3 PDGFaR and MBP mRNAs expression level in the spinal cord. mRNA levels were studied by real-time PCR. Results are expressed as
relative gene expression, from data obtained by using the equation 2-ΔΔCT . Results are presented as mean ± SEM. Eight animals were included
in each group (male and female) at each time point. Panels A and B refers to the gender effect in control groups, panels C and D refers to the
disease effect. PDGFaR mRNA expression level was higher in control males than in control females (A. Student’s t test *p = 0.0175), and MBP
mRNA in control males was 6 times higher than in control females (B. Student’s t test ***p < 0.0004). C: Relative expression of PDGFaR mRNA
temporal profile in EAE animals at 14, 21 and 40 DPI, in females (white triangle) and males (black circle), compared with respective/own sex
control group. The statistical analysis (two-way ANOVA) indicates a gender effect (*** p < 0.0001, F(1,50) = 18.08) and a disease effect (* p =
0.0259, F(3,50) = 3.358; Bonferroni post-test: control, * p < 0.05). D: Relative expression of MBP mRNA in EAE at the different disease phases
compared with control sex group. The statistical analysis (two-way ANOVA) indicates a gender effect (*** p < 0.0001, F(1,46) = 51.51) and a
disease effect (*** p = 0.0004, F(3,46) = 7.454; Bonferroni post-test: control, ** p < 0.01; 14 DPI, ** p < 0.01; 21 DPI, *** p < 0.001; 40 DPI,
* p < 0.05).
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Figure 4 Spinal cord MBP protein level in control rats. The levels of MBP protein, isoforms 21.5, 18.5 and 17.5 KDa were studied using
Western-blot. The graphs in A, B and C show the results of densitometric analysis after normalizing MBP with GAPDH (38 KDa). Results are
expressed as mean R.O.D. (relative optical density) values ± SEM. D: representative blot with the bands corresponding to female and male
GAPDH (38 KDa) and MBP 21.5 18.5 and 17.5 KDa isoforms. No differences were found between male and female control rats for the
investigated MBP isoforms.
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the ataxia symptom in EAE, where inflammatory cellular
infiltrates are scare in this disease model [26]. While the
clinical profile of the disease differs between sexes being
more severe in female than male rats, the inflammatory
cellular infiltration in the spinal cord is lower in females,
but produces a stronger astroglial reaction than in
males. Moreover, disease-induced alteration of several
markers is different between the two sexes. In particular,
a strong gender-dependent difference in MBP and
PDGFaR mRNA expression level in the spinal cord of
healthy animals was found, which correspond to a dif-
ferent regulation during the disease.
EAE in male and female Dark Agouti rats
Here we confirm that both male and female Dark Agouti
rats are highly susceptible to EAE [26]. While the clinical
Figure 5 PDGFaR and MBP mRNA expression level in the cerebellum. mRNA levels were studied by real-time PCR. Results are expressed as
relative gene expression, from data obtained by using the equation 2-ΔΔCT . Results are presented as mean ± SEM. Eight animals were included
in each group (male and female) at each time point. Panels A and B refers to the gender effect in control groups, panels C and D refers to the
disease effect. No differences were observed in PDGFaR and MBP mRNA expression in female and male healthy controls (A, B), such as in
PDGFaR mRNA expression in female (white triangle) and male (black circle) EAE animals at different DPI (C). On the contrary, statistical analysis
(two-way ANOVA) shows that relative MBP mRNA expression in EAE animals in different in male and female rats (** p = 0.0028, F(1,52) = 9.831)
and at different time points (*** p < 0.0001, F(3,52) = 25.14; Bonferroni post-test: 40 DPI, ** p < 0.01).
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score profile in the acute phase is similar in males and
females, male rats show a more pronounced recovery
than female rats. In this EAE model, a massive infiltration
by inflammatory cells, and a massive demyelination were
observed in the spinal cord, whereas small and localized
lesions were spread over the main white tracts, including
the cerebellar peduncoli, corpus callosum and optic
nerve [15,16,26]. The remyelination process starts quite
early also in Dark Agouti rats, but it is not yet complete
at 40 DPI [16]. In spite of the fact that severity of inflam-
matory infiltrate in the spinal cord is lower in female
compared to male rats, astroglial reaction is more pro-
nounced in female than in male rats. This could be
related to humoral rather cellular immune reaction.
Figure 6 GAD65 and GAD67 mRNAs expression level in the cerebellum. mRNA levels were studied by real-time PCR. Results are expressed
as relative gene expression, from data obtained by using the equation 2-ΔΔCT . Results are presented as mean ± SEM. Eight animals were
included in each group (male and female) at each time point. Panels A and B refers to the gender effect in control groups, panels C and D
refers to the disease effect. No differences were observed in GAD65 and GAD67 mRNA expression in female and male healthy controls (A, B).
Statistical analysis (two-way ANOVA) shows that relative GAD65 and GAD67 mRNA expression in EAE animals is similar in male (white triangle)
and female (black circle) rats (p = 0.3393 and p = 0.2009, respectively), whereas both mRNAs differ at different time points (disease effect: GAD65
**p = 0.0023, F(3,52) = 5.528; GAD67 *p = 0.0171, F(3,52) = 3.708).
Massella et al. BMC Neuroscience 2012, 13:12
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Overall, the females of all the species used for MS models
display stronger immune responses than males [26-28].
This is attributed to cytokines production [29,30]. For
example, cytokine IL-13 is implicated in gender differ-
ences in EAE severity in C57BL/6 mice, where the
absence of the anti-inflammatory IL-13 entails lower sus-
ceptibility to EAE in females vs males or WT females
with normal levels of IL-13 [31].
Gender-dependent differences in white matter during
health and inflammatory-demyelinating disease
When comparing the expression level of the genes
included in the study in male vs female healthy rats, the
most significant result was the 5-fold higher MBP and the
2.5-fold higher PDGFaR expression in males than females
in the spinal cord, but not in the cerebellum. This differ-
ence is not present at protein level, and, more generally,
no significant differences in myelin sheaths in the spinal
cord were found between male and female rats. This result
might suggest that MBP synthesis could be regulated in a
different way at post-transcriptional and translational
levels in males and females. In fact, mRNA levels and pro-
tein levels do not always correlate [32,33] and this might
be due to the post-transcriptional mechanisms playing
and/or to the different in vivo half life of proteins. Gonadal
steroid and neurosteroid may elicit effects through non-
genomic mechanisms via ERs localized on the plasma
membrane, and ligand-independent pathways to activate
ERs have been also described [34]. Moreover, the mechan-
isms controlling the rates of degradation/synthesis for a
given mRNA and protein are not homogeneous, even
within proteins that have similar functions [33]. Technical
limits of the methods for quantifying mRNA and proteins
should also be taken into account.
More generally, the issue of gender-related difference in
the anatomy of white tracts is complex and controversial.
The gender-dependent difference in PDGFaR and MBP
mRNA in the spinal cord correlates with data from Cer-
ghet et al. [35,36] in mice. They found that the density of
oligodendrocytes and the content of several myelin pro-
teins in white tracts is higher in males than in females,
whereas the lifespan of oligodendrocytes is shorter in
females than in males, thus suggesting that myelin turn-
over is greater in females than in males. It may thus be
argued that males have a greater functional reserve than
females, whereas females have a greater vulnerability
related to higher myelin protein turnover.
We and others already described the variation of MBP
protein content, such as different markers for OPCs in
male and female rats during EAE [13,15,16,37]. In this
Figure 7 NGF, BDNF, p75 and trkA mRNAs expression level in the cerebellum. mRNA levels were studied by real-time PCR. Results are
expressed as relative gene expression, from data obtained by using the equation 2-ΔΔCT . Results are presented as mean ± SEM. Eight animals
were included in each group (male and female) at each time point. Panels A to D refers to the gender effect in control groups, panels E and H
refer to the disease effect. No differences female and male healthy controls were observed in this group of transcripts (A, B). Statistical analysis
(two-way ANOVA) shows that mRNA expression in EAE animals is similar in male (black circle) and female (white triangle) rats for all transcripts,
whereas they differ at different time points (NGF: *p = 0.0253, F(3,53) = 3.365; p75: *** p < 0.0001 F(3,52) = 9.878; trkA: ** p = 0.0029, F(3,52) =
5.299).
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study we report that there is a gender-dependent differ-
ence in the regulation of PDGFaR and MBP during the
experimental disease, involving both genes in the spinal
cord, and MBP, only in the cerebellum. This correlates
with other reports describing differences in remyelination
in old male and female rats [38] and in cuprizone intoxi-
cation model (reversible inflammatory demyelination)
[39].
Neurotrophins and neuronal markers in inflammatory-
demyelinating diseases
The EAE model in rodents (and primates) allows neuro-
nal distress/damage to be investigated. We already
described how the expression level of the acetylcholine
synthesis enzyme choline acetyltransferase mRNA level
was transiently reduced in motor neurons in the spinal
cord [17] and in cholinergic neuron of the basal fore-
brain [18] during EAE. Here investigation was focused
on cerebellum, which is involved in motor symptoms in
EAE. In spite of scant inflammation and demyelination,
a grey matter atrophy [21] and a Purkinje cell loss [40]
has been described in the cerebellum. As index of neu-
ronal injury, we investigated the expression level of the
mRNAs encoding for the GABA synthesis enzyme g-
aminobutyric acid decarboxylase (GAD) [41]. A transi-
ent down-regulation of both GAD65 and GAD67 was
observed in male and female EAE rats, thus confirming
that the acute phase of the disease is associated with
reversible neuron distress.
Due to the neurotrophins role as endogenous neuro-
protectors, their expression levels were investigated dur-
ing EAE, focusing on NGF and BDNF. Previous results
from our laboratory have described higher levels of NGF
in certain brain areas, like the thalamus and cerebral
cortex, but not the spinal cord, in EAE compared to
healthy rats, associated to a strong up-regulation of p75-
and trkA-like immunoreactivity [13]. This up-regulation
diminishes over time and a drop in NGF mRNA expres-
sion level was reported in the cerebral cortex at 104
DPI [18]. Here we confirm the up-regulation of NGF
and its high-affinity receptor trkA mRNA in the cerebel-
lum in both male and female in the early, inflammatory
phase of EAE, while BDNF is down-regulated at the
same times. NGF, but also BDNF, modulate inflamma-
tion and immune cell function in many diseases [42-45].
Both the high and low affinity NGF receptors are widely
expressed in the immune system, thus indicating a
potential for responding to this neurotrophin through
an autocrine mechanism [43,45]. NGF increase during
EAE may possibly also result in increased neuroprotec-
tion [46], working with the marmoset model, showed
that NGF icv administration delayed the onset of clinical
EAE, and also prevented the full development of EAE
lesions. NGF administration also influences EAE
development and progression in rats [47] by reducing
the severity of the disease compared to that in saline
treated EAE mice.
The low-affinity receptor p75 is also up-regulated.
Notably, the up-regulation of p75 in Purkinje neurons
has been described in EAE [48]. The p75 up-regulation
in EAE could be related to the Purkinje neurons death
and cerebellar atrophy, since p75 can induce autophagy
and death in these cells [49].
Since the original report describing the different con-
tent of NGF in the submaxillary gland in male and
female mice [50], many other reports have illustrated
sexually dimorphic distribution of NGF in tissues and
plasma of different animal species [51-53]. The cerebel-
lum and particularly the Purkinje cells have been recog-
nized as a major source for neurosteroid production
[54], and we reported that neurosteroids are differen-
tially regulated in the cerebellum of control male and
female rats, such as during EAE [20]. Our mRNA data
indicate that there are no sex differences in the NGF
and BDNF levels in cerebellum either in healthy and
EAE rats, thus confirming previous reports suggesting
that neurotrophin levels do not correlate with estrogen
levels in females or with estrogen or testosterone levels
in males at this age [55,56].
Conclusions
Differences in vulnerability and disease evolution have
already given rise to clinical trials for MS based on
gonadal steroids. With regard to animal models of
inflammatory-demyelinating diseases, it has recently
been reported that the combined administration of 17
beta-estradiol and progesterone prevents cuprizone-pro-
voked demyelination of the corpus callosum in male
mice [57]. A similar effect of combined treatment was
also found in MOG (40-45)-induced EAE mice [58].
However, rational future prospects regarding the use of
sex steroids as adjuvant therapy in MS should be based
on the identification of the pathological process, cell
type, and molecular pathways positively affected by ster-
oids with regard to disease onset and progression. This
study provides a description of the gender-dependent
and disease-dependent regulation of markers for these
different processes in a well-established animal model,
suggesting that demyelination/remyelination might be a
target for gender-dependent therapies.
Methods
Animals, EAE induction, groups size
Dark-Agouti (Harlan, Italy) male and female rats, 150-
175 g body weight were used in this study. In both
female and male rats, a group was sensitized with a
medium containing 0.15 g/ml guinea pig spinal cord tis-
sue in complete Freund’s adjuvant (CFA, Sigma), 50% v/
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v, to which 5 mg/ml of heat-inactivated Mycobacterium
(Difco H37Ra) was added. Un-injected rats were used as
controls. Rats were regularly weighed and examined for
clinical signs of EAE by a trained observer according to
a semiquantitative score: 1 = loss of tail tone, 2 = mono
or bilateral weakness of hind legs or middle ataxia, 3 =
ataxia or paralysis, 4 = severe hind legs paralysis, 5 =
severe hind leg paralysis and urinary incontinence. To
determine the different phases of the estrous cycle,
female rats were monitored by daily vaginal smears and
only those demonstrating at least two consecutive 4-day
cycles were used in the study and killed on the day of
proestrus. Tissues were collected in two independent
experiments, the first for molecular biology studies, the
second for morphology and western blotting. Sixty-four
animals (32 females and 32 males) were included in the
first experiment; eight animals were included in each
time-point groups (sacrificed 14, 21, 40 DPI) for both
male and female, and for un-injected animals. Twenty-
four animals (12 females and 12 males) were include in
the second experiment, were tissue was collected at 14
DPI. All animal protocols described herein were carried
out according to the European Community Council
Directives (86/609/EEC) and approved by the intramural
ethical committee for animal experimentation of
Bologna University and Ministry of Health, comply with
the guidelines published in the NIH Guide for the Care
and Use of Laboratory Animals.
Histology, histochemistry and immunohistochemistry
Six animals/group were included in this part of the study.
EAE animals were killed at 14 DPI, i.e. during the acute
phase of the disease. The lumbar tract of the spinal cord
was rapidly dissected out, briefly washed in PBS and then
fixed using a paraformaldehyde 4% + saturated picric
acid 14% solution in PBS 0.2 M, pH 6.9 for 12 hours (h).
Cryostat sections (14 μm) were then collected from the
spinal cord. The extent of inflammation, demyelination
and astroglial rection was evaluated on tissue sections
stained with hematoxylin and eosin to visualize infiltrate
cells, with FluoroMyelin™ Fluorescence Myelin Staining
(Molecular Probes, Eugene, OR) for the myelin sheaths.
Indirect immunofluorescence (IF) procedures were used
to visualize the anti-fibrillary acid protein (GFAP, Chemi-
con International Inc. Temecula, CA, USA). Briefly, sec-
tions were first incubated in 0.1 M phosphate buffered
saline (PBS) at room temperature for 10-30 min, followed
by incubation at 4°C for 24 h in a humid atmosphere
with the primary antibodies diluted in PBS containing
0.3% Triton X-100, v/v. After rinsing in PBS for 20 min
(2 × 10 min), sections were incubated at 37°C for 30 min
in a humid atmosphere with the secondary antisera con-
jugated with different fluorochromes diluted in PBS/Tri-
ton X-100 0.3%. Sections were then rinsed in PBS (as
above) and mounted in glycerol containing 1,4-phenylen-
diamine 0.1 g/l (Sigma). Images were taken by Olympus
AX70-PROVIS microscope equipped with motorized
z-stage control and F-VIEW II CCD Camera. The inflam-
matory infiltration was evaluated by two independent
operators in blind on 5 replicate sections per animal, by
counting the number and severity of cellular infiltrates
over each, entire coronal section. Cellular infiltrates were
scored as follows: 0, none; 1, a few inflammatory cells; 2,
organization of perivascular infiltrates; 3, increasing
severity of perivascular cuffing with extension into the
adjacent tissue [59-61]. The inflammation score,
expressed as score/section, derives from the sum of infil-
tration score in each cellular infiltrate. To minimize the
bias due to random distribution of the demyelinating
lesions, the FluoroMyelin and GFAP-staining were both
measured in the fasciculus gracilis, and calculated as per-
centage positive areas using the Image ProPlus software
(Imaging Research Inc, St. Catharines, Ont., Canada).
Myelin sheath thickness was measured on confocal
images (Olympus FluoView 500) using Image ProPlus
software (MediaCybernetics, Bethesda, MD). The G-ratio
(ratio of axon diameter to total fibre diameter) was calcu-
lated on confocal images by dividing the circumference
of an axon without myelin by the circumference of the
same axon including myelin. At least 250 fibers/group
were included in the analysis.
RNA isolation, reverse transcription and Semiquantitative
real-time PCR
Total RNA was prepared by following manufacture’s
instructions (Mini RNeasy Kit, Qiagen, Milan, Italy).
RNAs were first subjected to DNase treatment (0.1 U/μl,
1× DNase buffer, 4 U/μl RNase inhibitor, all from Fermen-
tas, Life Sciences, Milan, Italy) by incubating at 37°C for
30 min. First strand cDNAs were obtained using 10 U/μl
of the M-Moloney murine leukaemia virus (MuLV)
reverse transcriptase enzyme (Fermentas), 1 mM of each d
(NTP)s (Fermentas), 5 μM of pd(N)6 random primers
(Roche, Molecular Biochemical’s, Indianapolis, IN, USA)
and 1 U/μl oligo(dT)18 (Fermentas). In order to discard
possible contamination of genomic DNA in isolated
RNAs, one sample with no reverse transcriptase enzyme
(no RT sample) was processed in parallel to the others
and tested by real-time PCR for every pair of primers
used. PCR reactions were performed with the Mx3005P™
real-time PCR system (Stratagene, CA, USA) using SYBR-
green I dye. All primers used for SYBR-green real-time
PCR were designer with the Beacon Designer software
(BD 5.0, Premier Biosoft International, Palo Alto, CA,
USA); primer sequences have been included in Table 1.
The housekeeping gene GAPDH was used to normalize
the amount of retro-transcribed mRNA used for PCR.
Reactions were performed in a final volume of 25 μl
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consisting on 1× master mix, (Fermentas) and 0.4 μM of
both forward and reverse primers. Two steps were per-
formed: 1. denaturation (95°C, 10 min); 2. annealing/
extension (40 cycles of: 95°C for 15 sec, 60°C for 30 sec);
at the end of PCR reaction the melting curve of amplified
products was always performed.
The efficiency of each pair of used primers was calcu-
lated by amplifying cDNA serial dilutions in the conditions
above described obtaining efficiency values in the range of
95-102%. The 2^(-ΔΔCT
) method was used for the calcula-
tion of gene expression relative to a given reference group
(CT, threshold cycle). When comparing gene expression
between sexes,ΔΔCT was calculated as follow: ΔΔCT =
(CT target gene- CT GAPDH) female - (CT target gene- CT
GAPDH) male. When instead comparing gene expression
between healthy (Control) and EAE animals at different
phases of the disease, the ΔΔCT formula was: ΔΔCT = (CT
target gene- CT GAPDH) Control - (CT target gene- CT GAPDH)
EAE acute (14 DPI), ΔΔCT = (CT target gene- CT GAPDH)
Control - (CT target gene- CT GAPDH) EAE remission (21
DPI), ΔΔCT = (CT target gene- CT GAPDH) Control - (CT target
gene- CT GAPDH) EAE chronic (40 DPI).
The specificity of real-time PCR reactions was evi-
denced by the melting curve of the amplified products,
obtaining a unique peak at the correspondent melting
temperature (Tm) (Figure 3E). No CT was obtained after
real-time PCR of no RT sample for any of the pair of
primers used. Template controls gave always no CT as
well. Random amplified products were resolved in a
2.5% agarose gel and TAE electrophoresis buffer, obtain-
ing a unique band of the expected size. DNA marker of
100 bp ladder (Fermentas) was used.
Western blotting procedure
Tissue homogenates were prepared using a lysing buffer
consisting on 10 mM Hepes, 1 mM DTT, pH 7.5 and pro-
tease inhibitor cocktail (Sigma). Equal amounts of protein,
concentrations determined by Lowry method with the
Protein assay kit (Bio-Rad, Hercules, California, USA),
were separated in 15% SDS-polyacrylamide gels and elec-
troblotted to nitrocellulose membranes. In order to block
nonspecific protein binding sites, filters were incubated
with blocking solution (Pierce, Rockford, IL, USA) for 2 h
at room temperature and primary antibodies were then
incubated overnight at 4°C. After washing for 1 hour with
TTBS (TBS-0.05% Tween-20), filters were incubated with
secondary antibodies for 30 min at room temperature and
washed again for another hour. Rabbit polyclonal anti-
MBP (DAKO), dilution 1:2000 and GAPDH (glyceralde-
hyde 3-phosphate dehydrogenase) (Millipore, Milan, Italy),
dilution 1:150 were used as primary antibodies while anti-
rabbit (1:30,000) and anti-mouse (1:2000), respectively,
antiserum conjugated to horseradish peroxidase (DAKO)
were used as secondary antibody. Finally, proteins were
detected using an ECL chemioluminescent kit (Pierce) and
exposition to radiographic film. Densitometric analysis
was performed using the AIS Imaging System software
(Ontario, Canada) and the data obtained statistically ana-
lysed and represented using PrismGraph software (Graph-
Pad Software, San Diego, CA, USA). Seven animals/group
were used to perform these studies.
Data presentation and statistical analysis
For mRNAs expression data, we first analyzed the differ-
ence between female and male control animals (data nor-
malized vs female, because the disease is usually induced
in female rats.). Student’s t test was used for the statistical
analysis. Since the aim of the study was to investigate the
disease effect at different time point in male and female
rats, we then analyzed the disease and gender influence by
two-way ANOVA and Bonferroni post-test. Results for
two-way ANOVA are reported in the figures and figure
legends. Morphological data were analyzed by Student’s t
test, and clinical data by two-way ANOVA. Results were
considered significant when the probability of their occur-
rence by chance alone was less than 5%. GraphPad Soft-
ware (San Diego, CA, USA) was used for statistics and
graph preparation.
Abbreviations
BDNF: Brain-derived neurotrophic factor; CFA: complete Freund’s adjuvant;
CNS: Central nervous system; DPI: day post-immunization; EAE: experimental
allergic encephalomyelitis; GAD: γ-aminobutyric acid decarboxylase; GABA: γ-
aminobutyric acid; GAPDH: glyceraldehyde 3-phosphate dehydrogenase;
GFAP: anti-fibrillary acid protein; MBP: myelin basic protein; MOG: myelin
oligodendrocyte glycoprotein; MS: Multiple sclerosis; NGF: Nerve growth
factor; OPCs: oligodendrocyte precursor cells; PDGF: platelet-derived growth
factor.
Table 1 Nucleotide sequences of primers used for gene
expression study by real-time semiquantitative PCR
assays.
Gene Primer Sequence
BDNF Forward
reverse
5’-gtgacagtattagcgagtg-3’
5’-gccttccttcgtgtaacc-3’
GAD65 Forward
reverse
5’-gcccgctataagatgtctc-3’
5’-aatcacactgtctgttcc-3’
GAD67 Forward
Reverse
5’-ggcatcttccactccttc-3’
5’-gacgactcttctcttccag-3’
MBP Forward
reverse
5’-catccttgactccatcgg-3’
5’-tttcatcttgggtcctctg-3’
NGF Forward
reverse
5’-gacgactcttctcttccag-3’
5’-cgtggctgtggtcttatctc-3’
PDGFaR Forward
reverse
5’- ctggtgcctgcctcctac-3’
5’- aactcgctggtcttgaacg-3’
p75 Forward
reverse
5’-agtggcatctctgtggac-3’
5’-ctacctcctcacgcttgg-3’
trk-A Forward
reverse
5’-tgaatctgtcctccaatgc-3’
5’-tgaagcgtctgtgtatgc-3’
GAPDH Forward
reverse
5’-ggcaagttcaatggcacagtcaag-3’
5’-acatactcagcaccagcatcacc-3’
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